Scotia Capital’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.95M Sell
164,026
-150,057
-48% -$8.75M 0.04% 215
2025
Q4
$16.9M Sell
314,083
-6,600
-2% -$318K 0.07% 155
2025
Q3
$14.5M Sell
320,683
-48,592
-13% -$2.27M 0.06% 168
2025
Q2
$17.1M Buy
369,275
+3,148
+0.9% +$155K 0.08% 145
2025
Q1
$22.3M Buy
366,127
+23,242
+7% +$1.35M 0.12% 106
2024
Q4
$19.4M Buy
342,885
+136,425
+66% +$7.62M 0.1% 117
2024
Q3
$10.7M Buy
206,460
+34,757
+20% +$1.63M 0.06% 172
2024
Q2
$7.13M Sell
171,703
-129,514
-43% -$5.8M 0.04% 200
2024
Q1
$16.3M Buy
301,217
+64,493
+27% +$3.29M 0.1% 127
2023
Q4
$12.1M Buy
236,724
+77,471
+49% +$4.07M 0.08% 145
2023
Q3
$9.24M Sell
159,253
-2,719
-2% -$167K 0.07% 161
2023
Q2
$10.4M Buy
161,972
+49,630
+44% +$3.33M 0.07% 154
2023
Q1
$7.79M Buy
112,342
+8,900
+9% +$628K 0.06% 176
2022
Q4
$7.44M Sell
103,442
-6,125
-6% -$462K 0.06% 177
2022
Q3
$7.79M Sell
109,567
-16,402
-13% -$1.19M 0.06% 166
2022
Q2
$9.7M Sell
125,969
-34,280
-21% -$2.61M 0.07% 157
2022
Q1
$11.7M Sell
160,249
-122,707
-43% -$8.24M 0.07% 155
2021
Q4
$17.6M Buy
282,956
+20,290
+8% +$1.19M 0.12% 111
2021
Q3
$15.5M Buy
262,666
+42,600
+19% +$2.81M 0.11% 114
2021
Q2
$14.7M Buy
220,066
+13
+0% +$848 0.11% 120
2021
Q1
$13.9M Buy
220,053
+5,060
+2% +$315K 0.11% 117
2020
Q4
$13.3M Buy
214,993
+26,371
+14% +$1.62M 0.12% 115
2020
Q3
$11.4M Buy
188,622
+4,551
+2% +$274K 0.12% 120
2020
Q2
$10.8M Buy
184,071
+18,989
+12% +$1.14M 0.15% 95
2020
Q1
$9.2M Buy
165,082
+12,803
+8% +$783K 0.13% 104
2019
Q4
$9.78M Sell
152,279
-35,600
-19% -$2.04M 0.11% 114
2019
Q3
$9.53M Buy
187,879
+7,118
+4% +$335K 0.11% 111
2019
Q2
$8.2M Buy
180,761
+84,596
+88% +$3.94M 0.1% 124
2019
Q1
$4.59M Buy
96,165
+305
+0.3% +$15.2K 0.06% 180
2018
Q4
$4.98M Sell
95,860
-6,144
-6% -$330K 0.07% 154
2018
Q3
$6.33M Sell
102,004
-18,156
-15% -$1.08M 0.08% 155
2018
Q2
$7.54M Sell
120,160
-60
-0% -$3.24K 0.1% 125
2018
Q1
$7.6M Sell
120,220
-12,080
-9% -$777K 0.1% 126
2017
Q4
$8.11M Sell
132,300
-444
-0.3% -$27.8K 0.11% 125
2017
Q3
$8.46M Sell
132,744
-28,175
-18% -$1.65M 0.12% 117
2017
Q2
$8.96M Buy
160,919
+9,067
+6% +$493K 0.15% 99
2017
Q1
$8.27M Buy
151,852
+27,480
+22% +$1.51M 0.14% 103
2016
Q4
$7.28M Buy
124,372
+29,808
+32% +$1.63M 0.12% 126
2016
Q3
$5.1M Buy
94,564
+34,016
+56% +$2.19M 0.09% 154
2016
Q2
$4.46M Buy
60,548
+1,415
+2% +$100K 0.09% 150
2016
Q1
$3.78M Buy
59,133
+14,094
+31% +$889K 0.08% 147
2015
Q4
$3.1M Hold
45,039
0.07% 202
2015
Q3
$2.67M Sell
45,039
-9,112
-17% -$578K 0.06% 213
2015
Q2
$3.56M Buy
54,151
+3,230
+6% +$213K 0.07% 195
2015
Q1
$3.29M Sell
50,921
-442
-0.9% -$27.7K 0.08% 162
2014
Q4
$3.03M Sell
51,363
-1,392
-3% -$78.5K 0.08% 162
2014
Q3
$2.7M Sell
52,755
-3,541
-6% -$177K 0.06% 183
2014
Q2
$2.73M Sell
56,296
-7,126
-11% -$351K 0.06% 172
2014
Q1
$3.29M Buy
63,422
+24,271
+62% +$1.29M 0.07% 153
2013
Q4
$2.08M Sell
39,151
-57,902
-60% -$2.95M 0.05% 186
2013
Q3
$4.49M Buy
97,053
+57,769
+147% +$2.54M 0.12% 111
2013
Q2
$1.75M Buy
+39,284
New +$1.71M 0.07% 168

Other funds holding BMY

Scotia Capital's BMY Position: Q1 2026 in Review

Scotia Capital reduced its Bristol-Myers Squibb (BMY) stake by 48% in Q1 2026, selling an estimated $8.75M and leaving 164,026 shares worth $9.95M. The position accounts for 0.04% of the portfolio, ranked #215.

Scotia Capital first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $22.3M in Q1 2025. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Scotia Capital held 164,026 shares of Bristol-Myers Squibb worth $9.95M as of Q1 2026.
  • Scotia Capital sold 150,057 Bristol-Myers Squibb shares in Q1 2026, an estimated $8.75M.
  • Bristol-Myers Squibb made up 0.04% of Scotia Capital's portfolio in Q1 2026, its #215 holding.
  • Scotia Capital first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Scotia Capital's Bristol-Myers Squibb position peaked at $22.3M in Q1 2025.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.